CY1109607T1 - Παραγωγο εποθιλονης για τη θεραπευτικη αντιμετωπιση του ηπατωματος και αλλων κακοηθων νοσων - Google Patents

Παραγωγο εποθιλονης για τη θεραπευτικη αντιμετωπιση του ηπατωματος και αλλων κακοηθων νοσων

Info

Publication number
CY1109607T1
CY1109607T1 CY20091101180T CY091101180T CY1109607T1 CY 1109607 T1 CY1109607 T1 CY 1109607T1 CY 20091101180 T CY20091101180 T CY 20091101180T CY 091101180 T CY091101180 T CY 091101180T CY 1109607 T1 CY1109607 T1 CY 1109607T1
Authority
CY
Cyprus
Prior art keywords
progressing
radiotherapy
cancer
treatment
diseases
Prior art date
Application number
CY20091101180T
Other languages
Greek (el)
English (en)
Inventor
John David Rothermel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1109607T1 publication Critical patent/CY1109607T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Silicon Polymers (AREA)
CY20091101180T 2002-05-01 2009-11-11 Παραγωγο εποθιλονης για τη θεραπευτικη αντιμετωπιση του ηπατωματος και αλλων κακοηθων νοσων CY1109607T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37706302P 2002-05-01 2002-05-01
EP03725129A EP1503756B1 (en) 2002-05-01 2003-04-30 Epothilone derivative for the treatment of hepatoma and other cancer diseases

Publications (1)

Publication Number Publication Date
CY1109607T1 true CY1109607T1 (el) 2014-08-13

Family

ID=29401440

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091101180T CY1109607T1 (el) 2002-05-01 2009-11-11 Παραγωγο εποθιλονης για τη θεραπευτικη αντιμετωπιση του ηπατωματος και αλλων κακοηθων νοσων

Country Status (23)

Country Link
US (2) US20050282873A1 (enExample)
EP (1) EP1503756B1 (enExample)
JP (1) JP2005528414A (enExample)
KR (1) KR20040106422A (enExample)
CN (1) CN1649585A (enExample)
AT (1) ATE439130T1 (enExample)
AU (1) AU2003227702B2 (enExample)
BR (1) BR0309711A (enExample)
CA (1) CA2483826C (enExample)
CY (1) CY1109607T1 (enExample)
DE (1) DE60328772D1 (enExample)
DK (1) DK1503756T3 (enExample)
ES (1) ES2330324T3 (enExample)
IL (1) IL164783A (enExample)
MX (1) MXPA04010853A (enExample)
NO (1) NO20045249L (enExample)
NZ (1) NZ536178A (enExample)
PL (1) PL211114B1 (enExample)
PT (1) PT1503756E (enExample)
RU (1) RU2358730C2 (enExample)
SI (1) SI1503756T1 (enExample)
WO (1) WO2003092683A1 (enExample)
ZA (1) ZA200408492B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2358730C2 (ru) * 2002-05-01 2009-06-20 Новартис Аг Производное эпотилона для лечения гепатомы и других раковых заболеваний
BRPI0414043A (pt) * 2003-09-02 2006-10-24 Novartis Ag tratamento de cáncer com epotilonas
US8394365B2 (en) * 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
EP1640004A1 (en) * 2004-09-24 2006-03-29 Schering Aktiengesellschaft Use of epothilones in the treatment of bone metastases and bone tumors or cancers
US20060134214A1 (en) * 2004-11-18 2006-06-22 Ismat Ullah Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
JP2008536479A (ja) 2005-02-11 2008-09-11 ユニバーシティ オブ サザン カリフォルニア ジスルフィド架橋を有するタンパク質の発現法
EP2029156A4 (en) 2006-05-01 2010-07-21 Univ Southern California COMBINATION THERAPY FOR CANCER TREATMENT
MX2008004267A (es) * 2008-03-28 2009-09-28 Posi Visionary Solutions Llp Metoclopramida de liberacion prolongada de 12 horas.
MX2008004268A (es) * 2008-03-28 2009-09-28 Posi Visionary Solutions Llp Metoclopramida de liberacion prolongada de 24 horas.
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
CN101747326B (zh) * 2010-01-12 2012-07-25 山东大学 18元大环内酯类埃博霉素化合物及其应用
WO2011146638A1 (en) 2010-05-18 2011-11-24 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6660758B1 (en) * 1996-12-13 2003-12-09 The Scripps Research Institute Epothilone analogs
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
ATE254615T1 (de) * 1999-02-22 2003-12-15 Biotechnolog Forschung Gmbh C-21 modifizierte epothilone
GB9918429D0 (en) * 1999-08-04 1999-10-06 Novartis Ag Organic compounds
RU2358730C2 (ru) * 2002-05-01 2009-06-20 Новартис Аг Производное эпотилона для лечения гепатомы и других раковых заболеваний

Also Published As

Publication number Publication date
IL164783A0 (en) 2005-12-18
CN1649585A (zh) 2005-08-03
RU2358730C2 (ru) 2009-06-20
PL211114B1 (pl) 2012-04-30
AU2003227702B2 (en) 2007-07-26
ES2330324T3 (es) 2009-12-09
CA2483826C (en) 2012-04-17
MXPA04010853A (es) 2005-02-14
US20080161369A1 (en) 2008-07-03
RU2004135307A (ru) 2005-09-10
NZ536178A (en) 2007-10-26
EP1503756B1 (en) 2009-08-12
IL164783A (en) 2011-08-31
PL371727A1 (en) 2005-06-27
DK1503756T3 (da) 2009-11-16
WO2003092683A1 (en) 2003-11-13
NO20045249L (no) 2005-01-26
AU2003227702A1 (en) 2003-11-17
HK1073601A1 (en) 2005-10-14
SI1503756T1 (sl) 2010-01-29
DE60328772D1 (de) 2009-09-24
CA2483826A1 (en) 2003-11-13
ZA200408492B (en) 2006-09-27
JP2005528414A (ja) 2005-09-22
US20050282873A1 (en) 2005-12-22
ATE439130T1 (de) 2009-08-15
PT1503756E (pt) 2009-10-28
BR0309711A (pt) 2005-02-09
EP1503756A1 (en) 2005-02-09
KR20040106422A (ko) 2004-12-17

Similar Documents

Publication Publication Date Title
CY1109607T1 (el) Παραγωγο εποθιλονης για τη θεραπευτικη αντιμετωπιση του ηπατωματος και αλλων κακοηθων νοσων
PH12019502586A1 (en) N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof
RU2012140185A (ru) Ингибирование ангиогенеза
NO20051575L (no) Bruk av quinazolinderivatet ZD6474 i kombinasjon med gemcitabin og valgfritt ioniserende straling i behandling av sykdommer forbundet med angiogenese og/eller okt kar-gjennomtrengelighet
NO20044475L (no) 2-(2,6-diklorfenyl)-diarulimidazoler
EA201201154A1 (ru) Ингибиторы фосфатидилинозит-3-киназы и способы их применения
NO339997B1 (no) Diarylhydantoinforbindelse, farmasøytisk sammensetning og anvendelse derav
NZ580009A (en) Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
BRPI0415525A (pt) derivados de imidazola e seu uso como agentes farmacêuticos
RU2018102963A (ru) Производные анилинпиримидина и их применения
RU2003137007A (ru) Новые пиридилцианогуанидиновые соединения
PT1390371E (pt) Oxazolo- e furopirimidinas e sua utilizacao em medicamentos contra tumores
CN110678452A (zh) 亚精胺及其衍生物的应用
RU2013131241A (ru) Композиции, содержащие ингибитор рi3к и ингибитор мек, а также их применение для лечения рака
ATE424208T1 (de) Proteinkinaseinhibitoren
NO20044498L (no) Kombinasjonsterapi for behandling av cancer
DE60331827D1 (de) Zusammensetzungen für die radioimmuntherapie von gehirn-tumoren
ATE435663T1 (de) Krebstherapie mit einem nukleären rezeptorliganden und einem hdac-hemmer
DK1653964T3 (da) Cancerkombinationsterapi omfattende AZD2171 og ZD1839
ATE386029T1 (de) Urokinase-inhibitoren
NO20064755L (no) Kombinasjonsterapi
NO20064754L (no) Kombinasjonsterapi
ATE400268T1 (de) Bisindolylmaleimid zur behandlung von prostatakrebs und akt-vermittelten erkrankungen
NO20051936L (no) Anvendelse av 4-pyridylmetyl-ftalazinderivater for fremstilling av et medikament for behandling av myelodysplastiske syndromer.
MX2009011692A (es) Uso de inhibidores de desacetilasa de histona (hdac) para el tratamiento de canceres gastrointestinales.